New Vaccine Solves for Emerging Enteric Disease in Young Pigs
MADISON, N.J., June 8, 2021 – Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), is expanding its SEQUIVITY® veterinary prescription vaccine platform to include a vaccine for sapovirus, an emerging virus causing diarrhea in young pigs.
“Awareness of clinical disease related to sapovirus has been growing in the last 2-3 years and veterinarians are now looking for tools to detect and manage this problem,” says Jack Creel, DVM, Associate Director, Swine Technical Services, Merck Animal Health. “It’s a perfect example of the role the SEQUIVITY platform can play in managing disease. We took the genetic sequence from sapovirus and inserted it into the platform and now have a vaccine that veterinarians can prescribe for herds impacted by this disease.”
Diarrhea is a common problem in young piglets and can be caused by a variety of pathogens. A recent publication led by Drs. Huigang Shen and Jianfeng Zhang of Iowa State University suggested porcine sapovirus in genogroup III can play an important role in piglet enteritis. In addition, production impacts from the resulting diarrhea can manifest as 1-2 pounds of lost expected weaning weight. And, polymerase chain reaction (PCR) provides an important diagnostic tool to detect the virus in the feces of pigs with clinical signs.1
To date, there are no commercial vaccines for sapovirus, and traditional vaccines can take years to develop. SEQUIVITY is different. Within a short period of time, this highly-advanced RNA Particle Technology can take genetic sequences for specific antigens found in
disease-producing pathogens and create a safe and precise vaccine solution.
“SEQUIVITY, introduced by Merck Animal Health in 2018, is revolutionary RNA technology and an excellent tool for veterinarians to utilize when dealing with a new disease or a specific on-farm challenge,” says Jeremy Maurer, VMD, a SEQUIVITY Diagnostic Analyst. At Merck Animal Health, we are committed to continually updating and expanding our SEQUIVITY offering. Sapovirus is one example. Others will be coming as the needs arise.”
To learn more about SEQUIVITY and to find answers to your advanced herd health challenges, visit SEQUIVITY.com or contact your local Merck Animal Health sales representative.
About Merck Animal Health
For 130 years, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook, and Twitter at @MerckAH.